Developing new therapeutic strategies for AML (Acute Myeloid Leukemia)

开发 AML（急性髓系白血病）的新治疗策略

• 批准号: 354022
• 负责人: Schimmer Aaron D
• 金额: $ 242.84万
• 依托单位: University Health Network (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-10-01 至 2023-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=354022&lang=en
• 关键词: Drug Development; Leukemia; Metabolism; Mitochondria; Translational Research

Aggressive induction chemotherapy produces complete remission in ~70% of patients with acute myeloid leukemia (AML), but most ultimately relapse, at least in part, due to the persistence of dormant stem cells that are resistant to standard chemotherapy.

积极诱导化疗可使约70%的急性髓性白血病（AML）患者完全缓解，但大多数最终复发，至少部分原因是对标准化疗耐药的休眠干细胞的持续存在。